At the onset of the pandemic, UK rheumatic disease patients had better well-being, lower disease activity, and lower risk of anxiety and depression. In addition, 81% of UK patients were able to contact their rheumatologist about possible side effects of treatment (vs 57.6% of the other REUMAVID countries).
This study is published in the journal Rheumatology Advances in Practice.
Link to the article: https://pubmed.ncbi.nlm.nih.gov/34988357/
